• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Cohance Lifesciences Limited — Board Meeting, 12-11-2025: Outcome of Board Meeting

    12-11-2025 | 06:41 pm

    Cohance Lifesciences' Board approved Q2 & H1 FY26 consolidated results. Q2 revenue hit ₹555.6 Cr (-8% YoY), EBITDA ₹128.9 Cr. H1 revenue was ₹1,104.9 Cr (+1.2%), EBITDA ₹263.0 Cr. Faced near-term headwinds but anticipates better H2. On track for $1B revenue (₹8,500 Cr) by 2030.

    No comments yet. Be the first to comment!

    All announcements from Cohance Lifesciences Limited